Description
The abstract states there is reciprocal influence between microbiota and brain inflammasome activation, but explicitly notes that ‘how this influence is precisely working is yet to be discovered.’ Understanding these mechanisms is critical for developing microbiome-based neurotherapeutics.
Gap type: open_question Source paper: The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology. (2021, Frontiers in immunology, PMID:33362788)
Resolution criteria
Resolution requires: (1) Germ-free or antibiotic-depleted mice with defined microbiota reconstitution show NLRP3 inflammasome assembly (ASC speck formation by confocal, caspase-1 activity by FLICA) in brain macrophages/microglia correlating with specific microbiome taxa (Spearman r>=0.5 for top 5 taxa) at phylum-to-species resolution by 16S sequencing; (2) Mechanism of CNS delivery: peripheral vagotomy or gut-selective antibiotic (poorly absorbed neomycin) reduces brain NLRP3 activation >=40% vs. systemic antibiotic, distinguishing vagal/neural from hematogenous routes; or specific microbiome-derived PAMP (LPS serotype, flagellin, peptidoglycan) identified by competitive ELISA or LC-MS/MS in brain parenchyma at >=10x plasma concentration; (3) Pharmacological intervention: NLRP3 inhibitor (MCC950) or gut-specific TLR4 antagonist reduces both microbiome-induced peripheral LPS elevation and brain IL-18/IL-1beta >=50%, with behavioral improvement in >=1 validated neurodegeneration assay. Observational correlation of microbiome composition with brain inflammation is insufficient.